跳至主要内容
临床试验/NCT01746342
NCT01746342已完成不适用

A Randomized, Controlled, Clinical Trial of Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea-Hypopnea in Multiple Sclerosis

McGill University1 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2013年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
49
试验地点
1
主要终点
Fatigue Severity Scale

研究概览

简要总结

Fatigue is highly prevalent among multiple sclerosis (MS) patients and has pervasive adverse effects on daily functioning and quality of life. The investigators found in a recent study that obstructive sleep apnea-hypopnea (OSAH) is the most common sleep abnormality in multiple sclerosis (MS) patients. There was also a significant relationship between OSAH and higher fatigue scores in MS patients. Preliminary work from the investigators in this group of subjects shows that treatment of sleep disorders (mostly OSAH) can improve fatigue and other symptoms in some MS patients. However, it is now necessary to systemically test the effect of OSAH treatment in a randomized, controlled study, to be sure that it really does improve fatigue and other symptoms. The best treatment for OSAH in the general population is continuous positive airway pressure (CPAP). This treatment has been well tolerated by most MS patients who have used the device at the investigators' center. This project will therefore be a randomized, controlled, clinical trial of CPAP in MS patients with OSAH. The effects of six months of CPAP treatment on fatigue as well as sleep quality, somnolence, pain, disability, and quality of life will be studied.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Diagnosis of multiple sclerosis by a neurologist based on standard criteria (Annals Neurol 2011; 69:292-302)
  • •Expanded Disability Status Scale score of 0 to 7.0
  • •MS-relapse free for >30 days prior to screening
  • •Pittsburgh sleep quality Index > 5
  • •Fatigue Severity Scale score >=4
  • •Montreal Cognitive Assessment (MoCA) >= 26
  • •diagnosis of OSAH by polysomnography showing AHI >= 15 events/h of sleep
  • •forced vital capacity >60% predicted

排除标准

  • •pregnancy or planned pregnancy
  • •psychiatric conditions which could preclude compliance with informed consent, study procedures, or study requirements
  • •other significant neurological, pulmonary, otorhinological, and medical disorders
  • •major depression within the past year
  • •any value of >1.5 times the upper limit or <0.75 the lower limit of the reference range for any standard clinical hemogram and biochemistry determinations which is clinically significant
  • •current treatment for OSAH
  • •presence of another untreated sleep disorder which is clinically significant
  • •very severe OSAH (safety criterion)defined as an AHI >30 with either a 4% O2 desaturation index >15 events/h OR work in a safety-critical position OR an ESS score >=15

研究组 & 干预措施

Effective CPAP

Active Comparator

Continuous positive airway pressure: effective fixed level determined by polysomnographic titration

干预措施: Effective continuous positive airway pressure (CPAP) (Device)

Sham CPAP

Sham Comparator

Continuous positive airway pressure device modified by manufacturer to deliver minimal pressure

干预措施: Sham continuous positive airway pressure (CPAP) (Device)

结局指标

主要结局

Fatigue Severity Scale

时间窗: Six months

次要结局

  • Pain visual analog scale(Three & Six months)
  • Multiple Sclerosis-specific quality of life measure-54 (MSQOL-54)(Three & Six months)
  • Expanded Disability Status Scale(Three & Six months)
  • Objective CPAP compliance(Three and Six Months)
  • Center for Epidemiological Studies-Depression Scale(Three & Six months)
  • Epworth Sleepiness Scale(Three & Six months)
  • Pittsburgh Sleep Quality Index(Three & Six months)
  • Cognitive evaluation(Six months)
  • Polysomnographic variables(Six months)
  • Fatigue Scale for Motor and Cognitive Functions(Three & Six months)
  • Fatigue Severity Scale(Three months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr John Kimoff

Co-Principal Investigator: with Dr Daria Trojan

McGill University

研究点 (1)

Loading locations...

相似试验